<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02635828</url>
  </required_header>
  <id_info>
    <org_study_id>2008H0170</org_study_id>
    <nct_id>NCT02635828</nct_id>
  </id_info>
  <brief_title>Effectiveness of Triple Therapy With Palonosetron for PON Prophylaxis</brief_title>
  <official_title>Studying the Effectiveness of Triple Therapy With Palonosetron, Dexamethasone and Promethazine for Prevention of Post Operative Nausea and Vomiting in High Risk Patients Undergoing Neurological Surgery and General Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postoperative nausea and vomiting (PONV) is a displeasing experience that distresses surgical
      patients during the first 24 hours after a surgical procedure. The incidence of postoperative
      nausea occurs in about 50%, the incidence of postoperative vomiting is about 30%, and in
      high-risk patients, the PONV rate could be as high as 80%. Therefore, the study design of
      this single arm, non-randomized, pilot study assessed the efficacy and safety profile of a
      triple therapy combination with palonosetron, dexamethasone and promethazine to prevent PONV
      in patients undergoing craniotomies under general anesthesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At induction of anesthesia, a triple therapy of palonosetron 0.075 mg IV, dexamethasone 10 mg
      IV and promethazine 25 mg IV was given as PONV prophylaxis. After surgery, subjects were
      transferred to the surgical intensive care unit (SICU) or post anesthesia care unit as
      clinically indicated. Ondansetron 4 mg IV was administered as primary rescue medication to
      subjects with PONV symptoms. PONV was assessed and collected every 24 hours for 5 days via
      direct interview and/or medical charts review.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PONV Incidence</measure>
    <time_frame>24 hours after end of surgery</time_frame>
    <description>The incidence of PONV</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Subjects Significant QTc Changes in the EKG</measure>
    <time_frame>24 and 120 hours/discharge after end of surgery</time_frame>
    <description>The incidence of significant QTc prolongation was measured by comparing baseline EKG, 24 hours and 120 hours after surgery</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Postoperative Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Triple therapy PONV prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At induction of anesthesia, a triple therapy of palonosetron 0.075 mg IV, dexamethasone 10 mg IV and promethazine 25 mg IV was given as PONV prophylaxis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palonosetron 0.075 mg IV</intervention_name>
    <description>At induction of anesthesia, palonosetron 0.075 mg IV was given as PONV prophylaxis.</description>
    <arm_group_label>Triple therapy PONV prophylaxis</arm_group_label>
    <other_name>Aloxi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone 10 mg IV</intervention_name>
    <description>At induction of anesthesia, dexamethasone 10 mg IV was given as PONV prophylaxis.</description>
    <arm_group_label>Triple therapy PONV prophylaxis</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Promethazine 25 mg IV</intervention_name>
    <description>At induction of anesthesia, promethazine 25 mg was given as PONV prophylaxis.</description>
    <arm_group_label>Triple therapy PONV prophylaxis</arm_group_label>
    <other_name>Phenergan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients, 18 to 85 years of age, of any race or gender. With an American Society
             of Anesthesiologist (ASA) physical status of I to III who are scheduled to undergo
             neurological surgery requiring opening of the cranium and Dura matter under general
             anesthesia, at Ohio State University Medical Center and who consent in writing to
             participating in this study.

          -  Post operative hospitalization expected to last at least 72 hours.

          -  Subjects whose surgery is expected to require at least 1 hours of general anesthesia

          -  Subjects who have a negative serum or urine pregnancy test within 1 day of surgery or
             who have been surgically sterilized or are postmenopausal.

        Exclusion Criteria:

          -  Subjects who are prisoners, pregnant, mentally ill, under the age of 18 or over the
             age of 85, ASA classification of V, alcohol or drug abusers.

          -  Subjects with known hypersensitivity to any 5-HT3 antagonist, to any agent that is
             part of the anesthesia regimen, or to other medications to be administered under this
             protocol.

          -  Subjects who are breastfeeding.

          -  Subjects who have had retching/vomiting or moderate to severe nausea in the 24 hours
             prior to anesthesia or suffer chronic nausea and/or vomiting

          -  Subjects who have been treated with any drug or other treatment with anti-emetic
             efficacy within the last 24 hours prior to the start of treatment.

          -  Subjects who have participated in a clinical trial of an investigational drug within
             30 days prior to surgery.

          -  Subjects who are participating in any other clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alberto A Uribe, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>The Ohio State University Wexner Medical Center</affiliation>
  </overall_official>
  <results_reference>
    <citation>Macario A, Weinger M, Carney S, Kim A. Which clinical anesthesia outcomes are important to avoid? The perspective of patients. Anesth Analg. 1999 Sep;89(3):652-8.</citation>
    <PMID>10475299</PMID>
  </results_reference>
  <results_reference>
    <citation>Kovac AL. Prevention and treatment of postoperative nausea and vomiting. Drugs. 2000 Feb;59(2):213-43. Review.</citation>
    <PMID>10730546</PMID>
  </results_reference>
  <results_reference>
    <citation>Fabling JM, Gan TJ, El-Moalem HE, Warner DS, Borel CO. A randomized, double-blinded comparison of ondansetron, droperidol, and placebo for prevention of postoperative nausea and vomiting after supratentorial craniotomy. Anesth Analg. 2000 Aug;91(2):358-61.</citation>
    <PMID>10910848</PMID>
  </results_reference>
  <results_reference>
    <citation>Gan TJ, Meyer T, Apfel CC, Chung F, Davis PJ, Eubanks S, Kovac A, Philip BK, Sessler DI, Temo J, Tramèr MR, Watcha M; Department of Anesthesiology, Duke University Medical Center. Consensus guidelines for managing postoperative nausea and vomiting. Anesth Analg. 2003 Jul;97(1):62-71, table of contents. Review.</citation>
    <PMID>12818945</PMID>
  </results_reference>
  <results_reference>
    <citation>Audibert G, Vial V. [Postoperative nausea and vomiting after neurosurgery (infratentorial and supratentorial surgery)]. Ann Fr Anesth Reanim. 2004 Apr;23(4):422-7. Review. French.</citation>
    <PMID>15120791</PMID>
  </results_reference>
  <results_reference>
    <citation>Manninen PH, Raman SK, Boyle K, el-Beheiry H. Early postoperative complications following neurosurgical procedures. Can J Anaesth. 1999 Jan;46(1):7-14.</citation>
    <PMID>10078396</PMID>
  </results_reference>
  <results_reference>
    <citation>Apfel CC, Läärä E, Koivuranta M, Greim CA, Roewer N. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology. 1999 Sep;91(3):693-700.</citation>
    <PMID>10485781</PMID>
  </results_reference>
  <results_reference>
    <citation>Sanger GJ, Andrews PL. Treatment of nausea and vomiting: gaps in our knowledge. Auton Neurosci. 2006 Oct 30;129(1-2):3-16. Epub 2006 Aug 24. Review.</citation>
    <PMID>16934536</PMID>
  </results_reference>
  <results_reference>
    <citation>Habib AS, Gan TJ. Combination therapy for postoperative nausea and vomiting - a more effective prophylaxis? Ambul Surg. 2001 Jul;9(2):59-71.</citation>
    <PMID>11454483</PMID>
  </results_reference>
  <results_reference>
    <citation>Ku CM, Ong BC. Postoperative nausea and vomiting: a review of current literature. Singapore Med J. 2003 Jul;44(7):366-74. Review.</citation>
    <PMID>14620731</PMID>
  </results_reference>
  <results_reference>
    <citation>Habib AS, El-Moalem HE, Gan TJ. The efficacy of the 5-HT3 receptor antagonists combined with droperidol for PONV prophylaxis is similar to their combination with dexamethasone. A meta-analysis of randomized controlled trials. Can J Anaesth. 2004 Apr;51(4):311-9.</citation>
    <PMID>15064259</PMID>
  </results_reference>
  <results_reference>
    <citation>Khalil S, Philbrook L, Rabb M, Wells L, Aves T, Villanueva G, Amhan M, Chuang AZ, Lemak NA. Ondansetron/promethazine combination or promethazine alone reduces nausea and vomiting after middle ear surgery. J Clin Anesth. 1999 Nov;11(7):596-600.</citation>
    <PMID>10624646</PMID>
  </results_reference>
  <results_reference>
    <citation>Board T, Board R. The role of 5-HT3 receptor antagonists in preventing postoperative nausea and vomiting. AORN J. 2006 Jan;83(1):209-16, 219-20. Review.</citation>
    <PMID>16528908</PMID>
  </results_reference>
  <results_reference>
    <citation>Siddiqui MA, Scott LJ. Palonosetron. Drugs. 2004;64(10):1125-32; discussion 1133-4. Review.</citation>
    <PMID>15139789</PMID>
  </results_reference>
  <results_reference>
    <citation>Rojas C, Stathis M, Thomas AG, Massuda EB, Alt J, Zhang J, Rubenstein E, Sebastiani S, Cantoreggi S, Snyder SH, Slusher B. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg. 2008 Aug;107(2):469-78. doi: 10.1213/ane.0b013e318172fa74. Erratum in: Anesth Analg. 2008 Oct;107(4):1405. Massuda, Edward B [corrected to Massuda, Ed B]; Rubenstein, Ed [corrected to Rubenstein, Edward]..</citation>
    <PMID>18633025</PMID>
  </results_reference>
  <results_reference>
    <citation>Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, Aapro M. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003 Oct;14(10):1570-7.</citation>
    <PMID>14504060</PMID>
  </results_reference>
  <results_reference>
    <citation>Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA, Bertoli LF, Yunus F, Morrica B, Lordick F, Macciocchi A. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol. 2006 Sep;17(9):1441-9. Epub 2006 Jun 9.</citation>
    <PMID>16766588</PMID>
  </results_reference>
  <results_reference>
    <citation>Candiotti KA, Kovac AL, Melson TI, Clerici G, Joo Gan T; Palonosetron 04-06 Study Group. A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo for preventing postoperative nausea and vomiting. Anesth Analg. 2008 Aug;107(2):445-51. doi: 10.1213/ane.0b013e31817b5ebb.</citation>
    <PMID>18633022</PMID>
  </results_reference>
  <results_reference>
    <citation>Kovac AL, Eberhart L, Kotarski J, Clerici G, Apfel C; Palonosetron 04-07 Study Group. A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo in preventing postoperative nausea and vomiting over a 72-hour period. Anesth Analg. 2008 Aug;107(2):439-44. doi: 10.1213/ane.0b013e31817abcd3.</citation>
    <PMID>18633021</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2015</study_first_submitted>
  <study_first_submitted_qc>December 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2015</study_first_posted>
  <results_first_submitted>March 28, 2016</results_first_submitted>
  <results_first_submitted_qc>March 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 5, 2017</results_first_posted>
  <last_update_submitted>March 24, 2017</last_update_submitted>
  <last_update_submitted_qc>March 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Sergio Bergese</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Palonosetron</keyword>
  <keyword>Craniotomy</keyword>
  <keyword>Nausea</keyword>
  <keyword>Vomiting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Palonosetron</mesh_term>
    <mesh_term>Promethazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will not be shared with other researchers.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>54 participants provided written consent for the study, and only 40 participants were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Triple Therapy PONV Prohylaxis</title>
          <description>At induction of anesthesia, a triple therapy of palonosetron 0.075 mg IV, dexamethasone 10 mg IV and promethazine 25 mg IV was given as PONV prophylaxis.
Palonosetron 0.075 mg IV: At induction of anesthesia, palonosetron 0.075 mg IV was given as PONV prophylaxis.
Dexamethasone 10 mg IV: At induction of anesthesia, dexamethasone 10 mg IV was given as PONV prophylaxis.
Promethazine 25 mg IV: At induction of anesthesia, promethazine 25 mg was given as PONV prophylaxis.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Triple Therapy PONV Prohylaxis</title>
          <description>At induction of anesthesia, a triple therapy of palonosetron 0.075 mg IV, dexamethasone 10 mg IV and promethazine 25 mg IV was given as PONV prophylaxis.
Palonosetron 0.075 mg IV: At induction of anesthesia, palonosetron 0.075 mg IV was given as PONV prophylaxis.
Dexamethasone 10 mg IV: At induction of anesthesia, dexamethasone 10 mg IV was given as PONV prophylaxis.
Promethazine 25 mg IV: At induction of anesthesia, promethazine 25 mg was given as PONV prophylaxis.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PONV Incidence</title>
        <description>The incidence of PONV</description>
        <time_frame>24 hours after end of surgery</time_frame>
        <population>Incidence of PONV</population>
        <group_list>
          <group group_id="O1">
            <title>Triple Therapy PONV Prohylaxis</title>
            <description>At induction of anesthesia, a triple therapy of palonosetron 0.075 mg IV, dexamethasone 10 mg IV and promethazine 25 mg IV was given as PONV prophylaxis.
Palonosetron 0.075 mg IV: At induction of anesthesia, palonosetron 0.075 mg IV was given as PONV prophylaxis.
Dexamethasone 10 mg IV: At induction of anesthesia, dexamethasone 10 mg IV was given as PONV prophylaxis.
Promethazine 25 mg IV: At induction of anesthesia, promethazine 25 mg was given as PONV prophylaxis.</description>
          </group>
        </group_list>
        <measure>
          <title>PONV Incidence</title>
          <description>The incidence of PONV</description>
          <population>Incidence of PONV</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Subjects Significant QTc Changes in the EKG</title>
        <description>The incidence of significant QTc prolongation was measured by comparing baseline EKG, 24 hours and 120 hours after surgery</description>
        <time_frame>24 and 120 hours/discharge after end of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Triple Therapy PONV Prohylaxis</title>
            <description>At induction of anesthesia, a triple therapy of palonosetron 0.075 mg IV, dexamethasone 10 mg IV and promethazine 25 mg IV was given as PONV prophylaxis.
Palonosetron 0.075 mg IV: At induction of anesthesia, palonosetron 0.075 mg IV was given as PONV prophylaxis.
Dexamethasone 10 mg IV: At induction of anesthesia, dexamethasone 10 mg IV was given as PONV prophylaxis.
Promethazine 25 mg IV: At induction of anesthesia, promethazine 25 mg was given as PONV prophylaxis.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Subjects Significant QTc Changes in the EKG</title>
          <description>The incidence of significant QTc prolongation was measured by comparing baseline EKG, 24 hours and 120 hours after surgery</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Triple Therapy PONV Prohylaxis</title>
          <description>At induction of anesthesia, a triple therapy of palonosetron 0.075 mg IV, dexamethasone 10 mg IV and promethazine 25 mg IV was given as PONV prophylaxis.
Palonosetron 0.075 mg IV: At induction of anesthesia, palonosetron 0.075 mg IV was given as PONV prophylaxis.
Dexamethasone 10 mg IV: At induction of anesthesia, dexamethasone 10 mg IV was given as PONV prophylaxis.
Promethazine 25 mg IV: At induction of anesthesia, promethazine 25 mg was given as PONV prophylaxis.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Our study also presented certain limitations that should be mentioned. To begin with, the study was designed without a control group; therefore, we were not able to compare the results from this regimen.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Director of Neuroanesthesia</name_or_title>
      <organization>The Ohio State Universtiy Wexner Medical Center</organization>
      <phone>6142933559</phone>
      <email>sergio.bergese@osumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

